Nalaganje...
Developing treatments for pulmonary arterial hypertension
Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for exa...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Medknow Publications & Media Pvt Ltd
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3641724/ https://ncbi.nlm.nih.gov/pubmed/23662193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2045-8932.109961 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|